Notice of Proposed Sale · 144
Roivant Sciences Ltd.
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ROIVANT SCIENCES LTD.
- Issuer CIK
- 0001635088
- SEC file number
- 001-40782
- Phone
- 44 207 400 3347
- Person for whose account securities are to be sold
- MAYUKH SUKHATME
- Relationships to issuer
- Officer · Director
- Street
- 7th Floor 50 Broadway
- City
- London
- State / country code
- X0
- Postal code
- SW1H 0DB
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 284,707 | 10,320,571.81 | 722,323,015 | 08/17/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/17/2026 | Exercise of Options Under a Registered Plan | Issuer | 284,707 | N | 08/17/2026 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| MAYUKH SUKHATME | Common | 08/14/2026 | 243,177 | 8,809,767.72 |
| MAYUKH SUKHATME | Common | 06/26/2026 | 500,000 | 17,039,650.00 |
| Mayukh Sukhatme | Common | 06/25/2026 | 500,000 | 17,051,141.93 |
Seller — prior-sale row 1, entry 1
- Name
- MAYUKH SUKHATME
- Street
- 7th Floor 50 Broadway
- City
- London
- State / country code
- X0
- Postal code
- SW1H 0DB
Seller — prior-sale row 2, entry 1
- Name
- MAYUKH SUKHATME
- Street
- 7th Floor 50 Broadway
- City
- London
- State / country code
- X0
- Postal code
- SW1H 0DB
Seller — prior-sale row 3, entry 1
- Name
- Mayukh Sukhatme
- Street
- 7th Floor 50 Broadway
- City
- London
- State / country code
- X0
- Postal code
- SW1H 0DB
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/17/2026
- Signed
- /s/ Mayukh Sukhatme
Company context
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes LISRAYA™ (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies. For more information, visit www.roivant.com.